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Introduction 
 
Scientific knowledge of genetics is expanding rapidly, which generates many 
possibilities for predicting and improving human health and life.
1 Individuals 
have high expectations about the potential benefits of genetics and are also 
increasingly  eager  to  learn  more  about  their  genetic  profile  and  future 
health.  Commercial  comp anies  seek  to  appease  the  hunger  for  genetic 
information by offering Direct -To-Consumer (DTC) genetic tests, also via 
internet. These tests are carried out without the involvement of a healthcare 
provider,  fail  to  provide  adequate  information  and  are  not  f oreseen  in 
genetic counselling services.
2 
 
After  undergoing  a  DTC  genetic  test  individuals  will  receive  information 
about the presence of genetic risks and hereditary diseases. The validity of 
these tests is, however, questionable. The use of DTC genetic tests may thus 
easily cause unjustified anxiety and spur individuals to undergo unnecessary 
follow-up tests and medical treatment, at considerable personal and societal 
expense. Despite these shortcomings, it can be argued from a legal point of 
view that unrestricted access to DTC genetic tests strengthens the personal 
autonomy  of  individuals.  It  empowers  them  to  take  independent 
responsibility for their health and future,
3 and it leaves them the decision of 
whether they want adequate information and genetic   counselling. At the 
same  time,  States  have  the  obligation  to  protect  individuals  against 
(potential) health risks, including exposure to misleading information upon 
the basis of which individuals may make decisions they would otherwise 
have rejected. This  positive obligation is well entrenched in international 
human rights law.
4  
 
Several  European  States  are  at  present  considering  the  introduction  of 
legislation to regulate the supply of and access to DTC genetic tests.
5 The 
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Netherlands is one of the few countries that already has such legislation in 
place,  in  an  effort  to  save  the  general  public  from  harm  resulting  from 
preventive  screening  tools.  The  internationally  widely  praised  Wet  op  het 
bevolkingsonderzoek (Act on population screening) seeks to offer protection 
against harmful screening programmes by way of a permit system.  
 
The  Netherlands  is  a  Member  State  of  the  Council  of  Europe  and  the 
European  Union.  These  organisations  influence,  in their  own specific  way, 
the freedom of Member States to regulate the supply of and access to DTC 
genetic tests. National measures seeking to protect the public against harm 
from  these  tests  have  to  abide  by  the  standards  adopted  by  these 
organisations. 
 
This paper seeks to examine whether the Wet op het bevolkingsonderzoek 
can serve as an example for other European countries. It aims to assess the 
effectiveness of this Act as well as its compliance with European standards. 
We start by describing the normative questions surrounding the supply of 
and access to DTC genetic testing by internet in section I. Then, we unravel 
the international, but particularly European, patchwork of (legal) standards 
concerning the supply of and access to DTC genetic tests through internet in 
section II. Section III provides an overview of Dutch legal standards and 
problems that emerge in practice when seeking to regulate the supply of 
screening programmes, including DTC genetic tests. Lastly, in section IV we 
formulate an answer to the above questions, followed by conclusions.  
 
I. DTC Genetic Testing 
 
Genetic  screening  can  be  defined  as  any  kind  of  test  being  offered  to  a 
person  or  group  of  individuals  with  the  aim  of  detecting  or  ruling  out  a 
hereditary  disease,  a  predisposition  to  such  a  disease  or  to  determine 
whether a person carries a genetic variant that may produce a hereditary 
disease in their offspring.
6 Individuals can buy a test kit for screening their 
DNA  on  the  internet  without  the  involvement  of  a  physician  or  genetic 
counselling. After visiting the online shop and ordering a  genetic test, the 
individual  will  receive  a  test  kit  from  the  company.  This  kit  commonly 
includes a tube for taking a DNA sample, such as saliva or a hair, to be 
returned to the company. Upon receiving the DNA sample, the company‘s 
laboratory starts the analytic process. A few weeks later the individual can 
download the test results using a simple code. 
In this respect it is important to make a distinction between presymptomatic 
diagnosis and susceptibility genetic tests. Presymptomatic diagnostic genetic 
tests are mostly aimed at discovering a monogenetic disease, that is to say 
a  gene  mutation  which,  by  definition,  will  almost  inevitably  lead  to  the 
development of disease at some point in later in life.
7 By contrast, testing for 
multiple genetic variants is generally associated with low risks of developing 
common health conditions and traits. A ‗positive‘ test result—meaning that 
an  affected  gene  has  been  detected—  generally  implies  a(n  enhanced) 
statistical risk but not a certainty of developing the disease later in life.
8 The 
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results  of  the  latter  susceptibility  tests  do  not  necessarily  accurately 
establish the risk of developing a disorder, because in most cases not all risk 
factors are included and additional relevant factors, such as family history 
and lifestyle, are not taken into account by the test. Furthermore, there are 
carrier  tests  that  have  been  developed  to  determine  whether  a  healthy 
person  or  couple  carries  a  relevant  mutation  for  an  autosomal  recessive 
disorder.
9  The majority of DTC genetic t ests concern susceptibility tests, 
sometimes in combination with presymptomatic diagnosis tests or carrier 
tests. 
 
Against this background it is not a surprise that the interpretation of test 
results can be challenging for a person, particularly for those  with limited 
knowledge of genetics and medical statistics. It is well known from various 
studies  on genetic counselling  that  complex  information  on  risk  factors is 
particularly difficult to handle for a layman, regardless of their background 
or education.
10 
 
I.1 Normative Questions Surrounding Access to DTC Genetic Testing 
 
DTC genetic tests have the potential to empower individuals to take more 
responsibility  for  their  health  and  life  by  providing  risk  assessment 
information.
11 However, individuals often overestimate the benefits of DTC 
genetic tests now that these tests are generally offered without adequate 
information. It is well known that individuals may take important health 
decisions  concerning  prevention  or  prophylactic  treatment  based  on 
incomplete or misunderstood information about their expected health.
12  
 
The validity and clinical utility of these tests are questionable and can even 
have detrimental effects for the individual concerned as well as others due to 
needless and invasive follow-up tests  or unnecessary medical treatment.
13 
Under human rights law, States are bound to protect individuals against 
such  serious  risks.  Unrestricted  access  to  DTC  genetic  tests  can  also 
interfere  with  other  fundamental  human  rights  and  interests  of  others. 
Individual genetic health information can, for example, reveal information 
about family members and could have implications for their health, thus 
directly  impacting  on  their  rights  and  interests.  If  follow -up  tests  and 
unnecessary medical treatment happen on a large scale, unrestricted access 
to DTC genetic tests may also indirectly threaten the accessibility of the 
health care system. 
States are then torn between Scylla and Charybdis
14 when confronted with 
the shortcomings of DTC genetic tests. Should they allow i ndividuals to 
freely make use of tests of questionable quality for the sake of respecting 
autonomous  decision  making,  or  should  health  concerns  prevail,  thus 
restricting the commercial activities of companies and inhibiting individual 
use of their products? 
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II. European Standards 
 
DTC genetic testing offered by internet companies is a cross border activity 
affecting millions of people across the European region. In order to uphold 
the same standards with respect to autonomy and protection it is important 
that  convergence  is  sought  between the  law and  policies  on screening  in 
different jurisdictions.
15 The main regional organisations in Europe, being the 
Council of Europe (Council) and the European Union (EU),  have developed 
standards regulating the supply of   and access to genetic tests for health 
purposes. These instruments also, and sometimes specifically, apply to DTC 
genetic tests. In this section we describe and examine the most important 
standards adopted within the context of the Council and the EU, relevant for 
the use of DTC genetic tests. 
II.1 European Convention on Human Rights  
 
The  Council  of  Europe‘s  most  important  legal  instrument,  the  European 
Convention for the Protection on Human Rights and Fundamental Freedoms 
(ECHR),
16 is of crucial importance when it comes to regulating the use of 
DTC genetic tests, even though the Convention does not contain a reference 
to the right to health or a right to health care. From the European Court of 
Human Rights‘ (ECtHR) case law it can, however, be seen that compliance 
with ECHR established rights also requires contracting States to the ECHR 
(henceforth: States Parties) to take adequate measures in the area of health 
promotion and the prevention of health risks. These duties to protect and 
ensure  the  enjoyment  of  Convention  rights  are  known  as  positive 
obligations, as opposed to negative obligations that are imposed on States 
Parties not to interfere with human behaviour and inter-human relations. 
 
The  Court‘s  doctrine  of  positive  obligations  is  essential  for  health  law, 
notably now that these obligations do not confine themselves to the vertical 
relations,  but  extend  to  horizontal  ones.  In  other  words,  by  imposing 
positive obligations regulating human conduct with respect to other private 
parties,  the  Court  acknowledges  that  States  Parties  should  also  uphold 
respect for human rights in the relations between private parties. By way of 
example, it can be recalled that the Court has held that States Parties are 
obliged  to  formulate  adequate  legislation  to  protect  the  integrity  of 
individuals against violations by others.
17  
According to the Court‘s standing case law, States Parties are bound by the 
positive obligation to protect their citizens against (potential) health risks.
18 
The State has equally emphasised the importance of adequate information, 
including informing the patient about health risks, as a precondition for 
informed consent.
19  In a number of cases the Court concluded that the 
failure to provide adequate information prior to a health intervention results 
in  a  violation  of  an  individual‘s  physical  integrity,  which  is  protected  by 
Article 8 of the ECHR.
20 
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It  can  be  argued  that  free  access  to  DTC  genetic  tests  strengthens  the 
individuals‘ autonomy, as protected by the right to private and family life.
21 
Autonomy, particularly relevant in the field of health care,
22 also means that 
States  have  to  respect  the  choices  of  harmful  activities  from  mentally 
competent  individuals.
23  However,  autonomous  decisions  have  to  be 
compatible with human dignity, the principle unde rlying all human rights. 
This  explains  why  the  Court  has  held  that  an  individual  cannot  legally 
consent to practices deemed to be at odds with human dignity, such as 
being tossed around to entertain others and gain oneself an income (dwarf 
tossing) or to engage in extremely violent sexual practices.
24  
 
It can be maintained that the requirement to obtain the individual‘s informed 
consent prior to a health intervention also entails obligations for companies 
offering DTC genetic tests – or at least a duty for States to ensure that these 
companies abide by the informed consent requirement.
25 From the case law 
of the ECtHR it follows that an individual can only agree with an interference 
with his/her private life in the field of health care after he/she has voluntarily 
and unambiguously consented to this on the basis of prior and adequate 
information.  It  can  be  debated  whether  there  is  lawful  consent  when 
companies offering DTC genetic tests fail to provide adequate information on 
such issues as the scientific validity of these tests, their limitations and the 
benefits as well as the risks.  
 
In  conclusion,  the  obligation  to  provide  adequate information  about  the 
health benefits and risks prior to obtaining the consent of an individual is a 
well-established  requirement  recognised  under  the  ECHR.  States  should 
ensure  that  this  requirement  is  also  upheld  in  the  so -called  horizontal 
relations. From a human rights perspective there are therefore good reasons 
for States to regulate the supply of and access to DTC genetic tests because 
of the (potential) health risks to individuals and the deficiencies with respect 
to adequate information and valid consent. 
II. 2 Biomedicine Convention 
 
Particularly  relevant  with  respect  to  the  use  of  DTC  genetic  tests  is  the 
Council‘s Convention for the Protection of Human Rights and Dignity of the 
Human  Being  with  regard  to  the  Application  of  Biology  and  Medicine 
(Biomedicine  Convention).  The  Convention  itself  consists  of  principles, 
rights, and standards applying to specific fields of biology and medicine. Yet 
only a certain number of principles, rights and standards have been clarified 
by  the  drafters.  Other  issues,  including  those  on  which  it  is  difficult  to 
achieve consensus, have been or will be dealt with in Additional Protocols. 
 
The Protocol concerning Genetic Testing for Health Purposes (the Protocol) 
deserves special attention. The Protocol, to be read in conjunction with the 
Biomedicine  Convention  itself, came  into  force  on 1  December 2009. The 
Protocol seeks to protect the human dignity and the fundamental rights and 
freedoms of individuals with regard to genetic testing for health purposes. 
The Protocol applies to all genetic tests whether they are provided publicly or 
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privately.  It  also  covers  genetic  tests  that  are  carried  out  for  health 
purposes, such  as  DTC  genetic  presymptomatic  diagnostic,  predictive  and 
carrier tests. Genetic tests carried out on the human embryo or foetus and 
for research purposes are, however, excluded from its scope.
26 The Protocol 
requires  States  Partie s  to  take  the  necessary  measures  to  ensure  that 
genetic tests meet generally accepted criteria of scientific validity and clinical 
validity. Clinical utility of genetic tests must, according to the Protocol, be an 
essential criterion for deciding to offer genetic tests to the public.
27 
 
The Protocol furthermore stipulates that when a genetic test is considered, 
the persons concerned shall be provided with prior appropriate information, 
notably  about  the  purpose  and  the  nature  of  the  test,  as  well  the 
implications of its results.
28 Appropriate genetic counselling should also be 
provided.
29 
 
States that have ratified this instrument need to uphold these standards,
30 
which are considered to reflect European  minimum  standards.  States  are 
explicitly  also  allowed  to  grant  potential  test  subjects  a  higher  level  of 
protection.
31 It follows that the supply of and access to DTC genetic tests in 
European States, at least in those countries that have ratified the Protocol, 
should be in conformity with these standards. Failure   to guarantee these 
standards equals a violation of human rights for which States eventually can 
be held accountable.  
 
II.3 The Internal Market Rules of the European Union 
 
Despite the considerable powers of the EU in various areas of social life, the 
main responsibility for health policy and provision for health care rests with 
the Member States.
32 It is settled case-law of the European Court of Justice 
(ECJ) that EU law does not detract from the freedom of Member States to 
choose their own health security level.
33 Nevertheless, notably in the case of 
cross border activities, EU law indirectly regulates access to DTC genetic 
tests. States have the obligation to comply with the rules of European Free 
Market that  prohibit —amongst  others—measures  that  impair  free-market 
competitions. Thus Member States are in principle required to respect the 
free movement of goods, services and establishment when exercising their 
power in the field of health. 
 
As for EU law, it is important how to qualify DTC genetic tests. It is settled 
case-law  that  the  ECJ
34  will examine  in  principle  a  national measure in 
relation  to  one  freedom  if  a  restriction  relates  to  several  fundamental 
freedoms.  It  shall  appraise  a  national  measure  in  relation  to  two 
fundamental  freedoms  if  it  appears  t hat  one  of  them  is  not  entirely 
secondary to the other one.
35  
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In our opinion a DTC genetic test is not a good but rather a service because 
the test kit with the tube (good) is entirely secondary to the analytic process 
in the laboratory (service). In connection with this discussion, some authors 
argue that DTC genetic tests fall within the scope of Directive 98/79/EC on in 
vitro  diagnostic  medical  devices.  This  Directive  ensures  a  quality  review 
before ‗high risk‘ self tests (for instance self tests for HIV) are marketed.
36 
In our opinion DTC genetic tests are not covered by this Directive. In the 
first place this Directive does not apply to services. In the second place 
products of general laboratory use are not in vitro diagnostic.
37 The tube for 
taking a DNA sample has no particular diagnostic value and is not produced 
with special characteristics for testing.  
 
In the absence of harmonisation of DTC genetic tests EU Member States are 
under certain circumstances allowed to take measures, which restrict the 
free  movement  of  services  and  establishment  to  protect  their  citizens 
against (potential) health risks.
38  These measures have to be objectively 
necessary for the purpose, and the result could not be achieved through less 
restrictive  rules.  In  addition,  thes e  measures  should  not  discriminate 
services or the establishment on grounds of nationality.
39 Furthermore when 
measures derogate the free movement of services or establishment they 
must  pursue  its  goal  in  a  consistent  and  systematic  way.
40  Prior 
administrative  authorisation,  like  permit  systems,  must  be  based  on 
objective announce criteria that are stated well in advance.
41  
 
Reference should also be made to Directive 2000/31/EC on certain legal 
aspects of information society services, in particular electronic commerce, in 
the  Internal  Market  (E -  Commerce  Directive).  This  Directive  covers  the 
online  services  by  which  DTC  genetic  tests  are  offered  on  internet.  In 
principle  this  Directive  allows  a  permit  system,  which  is  meant  to  be 
exclusively for information society services. Information society services are 
services  that  are normally  provided for  remuneration,  at  a  distance,  by 
electronic means and at the individual request of a recipient of services.
42 
Member States may take measures to derogate the freedom to  provide 
information society services to protect health under the same conditions as 
we have described above.  
 
II.3.1 Recommendations and White Paper 
 
In 2004 the European Commission published 25 recommendations on the 
ethical, legal and social implications of genetic testing.
43 A multidisciplinary 
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expert group was invited by the Commission to discuss the implications of 
genetic  testing.  The  25  recommendations  are  the  results  of  the  expert 
groups work. They seek to be a starting point for the EU and Member States 
to consider an action plan for genetic testing and the recommendations can 
be used for implementation by policy-makers.  
 
According to the report underlying these recommendations, genetic testing 
should only be carried out in specialised laboratories under the supervision 
of  a  trained  geneticist.  The  application  of  genetic  testing  for non-medical 
reasons  requires  careful  consideration  with  regard  to  its  potential 
consequences  for  society.  The  report  also  requires that  genetic  testing in 
Europe has to be based on high quality scientific knowledge. A system for 
the validation of tests should be established by the EU. In the context, of 
human healthcare genetic tests should be offered only when there is a sound 
medical reason for testing. Furthermore the report stipulates that medical 
relevant  genetic  testing  has  always  be  a  free  personal  choice.  Therefore 
comprehensive information about genetic test should be available. Informed 
consent, the right to know and not to know, and genetic counselling must be 
guaranteed and are essential requirements for genetic tests, in particular for 
highly  predictive  tests  for  serious  disorders.  The  report  demands  test 
providers  to  ensure  that  the  information  they  provide  is  accurate  and  in 
agreement  with  international  quality  standards  according  to  the 
recommendations.  
 
The EU has presented its strategy toward health in a so called White Paper.
44 
This Paper sets out a framework to give direction to EU health policy until 
2013. The EU has pinpointed out objectives key areas t o develop more 
specific activities to promote health. Two of these key areas are protection 
of consumers against health threats and supporting new technologies and 
considering their implications.  
 
II.4 Preliminary Conclusions 
 
The  ECHR,  the  Biomedicine  Convention  and  the  Protocol  offer  an 
authoritative framework for the regulation of the use of DTC genetic tests 
across Europe. Not all States Parties to the ECHR, including the Netherlands, 
have, however, ratified the Biomedicine Convention, let alone the Protocol. 
That  does  not  mean  that  these  standards  have  no  meaning  for  these 
countries.  It  can  be  argued  that  the  adopted  norms  reflect  emerging 
European standards that can not always be enforced throughout Europe yet. 
When regulating the use of DTC genetic tests, the obligations enshrined in 
the ECHR, the Biomedicine Convention and the Protocol therefore have to be 
taken into account. 
 
The supply of and access to DTC genetic tests is in principle also regulated 
by the Internal Market Rules of the EU, even though there is discussion with 
respect  to  the  precise  qualification  of  a  DTC  genetic  test.  This  body  of 
legislation has to be respected by Member States considering the regulation 
of the use of DTC genetic testing. The EU has as yet not adopted a directive 
setting specific normative criteria for access to DTC genetic tests.  The EU 
Commissions recently adopted 25 recommendations on the ethical, legal and 
social implications of genetic testing that provide normative guidance as it 
relates to the supply of and access to DTC genetic tests. 
 
                                                                                                                              
(06/05/2004) and at http://ec.europa.eu/research/conferences/2004/genetic/pdf/report_en.pdf 
(06/052004). 
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In the absence of more elaborate standards with respect to the supply of 
and  access  to  DTC  genetic  tests  at  the  European  level,  States  enjoy  a 
considerable margin of appreciation to regulate the supply of and access to 
DTC  genetic  tests  in  the  way  they  deem  most  appropriate  to  find  a  fair 
balance  between  personal  autonomy  and  the  need  to  protect  individuals 
against the disadvantages of these tests. 
 
III.  Dutch Legal Standards 
 
In the Netherlands companies and health professionals are in principle free 
to  offer  health  testing  kits  to  the  public.  Some  forms  of  screening  can, 
however, only be carried out with a permit issued by the Minister of Health, 
Welfare and Sports. The criteria to be met by the applicant for these forms 
of  ‗high  risk  screening‘  are  laid  down  in  the  Act,  ‗Wet  op  het 
bevolkingsonderzoek‘ (the Act). This system was introduced to establish and 
guarantee  a  fair  balance  between  the  right  of  self-determination  of 
individuals  and  the  need  to  protect  them  against  (potentially)  harmful 
screenings techniques.
45  
 
In the Act, population screening is defined as: ―a medical examination which 
is carried out in response to an offer made to the entire population or to a 
section  thereof  and  to  detect  diseases  of  a  certain  kind  or  certain  risk 
indicators,  either  wholly  or  partly  for  the  benefit  of  the  persons  to  be 
examined‖.
46 Offering and practicing tests for detecting (risk indicators of) 
cancer  and  ‗incurable  diseases‘  without  a  licence  is  unlawful.
47  Moreover, 
performing  these  screening  methods  without  permission  is  a  punishable 
offence.
48  
According to the Act, the Dutch Minister of Health, Welfare and Sports grants 
the licence for screening (risk indicators for) of cancer or (risk indicators for) 
untreatable diseases, provided that the screening is scientifically sound, in 
accordance with the professional medical practice standards and maintains 
proper balance between health risks and benefits.
49 The Act does not set 
quality norms for the information to be provided to the (potenti al) test 
subjects,  consent,  the  use  of  samples,  and  counselling  to  be  provided. 
Nevertheless,  health  care  workers  and  companies  wishing  to  perform  a 
population  screening  programme  have  to  comply  with  the  professional 
medical practice standards that entail  the main rights of the patient as laid 
down in the Dutch Civil Code. 
III.1 Interpretation and Enforcement Problems 
 
The  Act  came  into  force  in  1996.  From  the  very  beginning  there  was 
confusion about its scope, and thus uncertainty about the requirements of 
obtaining a license. Over the last fourteen years the Dutch Health Council, a 
scientific  advisory  body  that  has  been  allotted  the  task  of  advising  the 
Minister on the provision of a license to applicants under the Act, has written 
seven reports seeking to clarify the realm of the Act.
50 Despite these helpful 
contributions certain uncertainties remain that are probably inherent to the 
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use  of  terms  like  ‗population  screening‘,  ‗offer‘  and  ‗incurable‘.  There has 
therefore been a call to revise this Act to enhance its effectiveness.
51 
 
Moreover, the Act has several loopholes. Companies use these for their own 
benefit, for example in the area DTC genetic screening. Enforcement of the 
Act is difficult because offering and performing screening for the (risk of) 
hereditary cancer and incurable diseases without a licence are prohibited, 
but only practicing without a legal permission is actionable. Dutch companies 
offer  screening  programmes  directly  to  the  public  on  internet  sites,  in 
newspapers  and  in  magazines.  They  do  this  without  a  licence  in  their 
homeland and practice screening across the border. Furthermore the Act 
does  not  cover  DTC  carrier  tests  whilst  these  tests  can  have  serious 
psychological and familial implications. The Act does not regulate the access 
to these tests because they do not detect the (risk of) hereditary disease of 
the individual but provides information about the risk of having a child with a 
genetic condition. 
 
III.2 Preliminary Conclusions  
 
The Dutch Act was not developed for nor does it exclusively regulate the use 
of DTC genetic tests. Nevertheless the Act does apply to DTC genetic tests 
due  to  the  fact  that  these  tests  fall  within  the  definition  of  population 
screening,  as  laid  down  in  the  Act.  Therefore,  the  Act  does  apply  legal 
quality standards to ‗high risk‘ DTC genetic tests.  
 
DTC genetic testing is classified as population screening because companies 
offer  their  genetic  services  directly  to  the  public.  The  key  word  in  the 
definition of the Act is ‗offer‘. The fact that individuals visit the web shop on 
their own initiative makes no difference when classifying DTC genetic tests 
as  population  screening. This means that  in the  Netherlands  offering  and 
practicing  screening  for  detecting  the  (risk  indicators  of)  cancer  and 
untreatable diseases without a licence is unlawful
52 and practicing without 
permission is a punishable offence.
53  
  
IV. Discussion  
 
Can the Dutch Act serve as an example for other European countries, when 
regulating  the  use  of  DTC  genetic  tests  in  a  way  that  is  consistent  with 
European  legal  standards?  Despite  various  initiatives  there  is  as  yet  no 
comprehensive  European  legal  framework  regulating  the  supply  of  and 
access  to  DTC  genetic  tests.  When  studying  the  different  existing 
instruments and documents adopted by the Council of Europe and the EU, 
there  appears  to  be  a  prevailing  opinion  that  the  validity  and  utility  of 
genetic tests are essential preconditions for allowing them to be offered to 
the public. Moreover, there is widespread (international) support for the idea 
that genetic tests, including DTC genetic tests, should be offered only under 
medical  supervision.
54  DTC  genetic  tests  with  risks  that  can  have  far 
reaching implications for the person concerned or his or her relatives should 
not  be  allowed  without  appr opriate  non -directive  genetic  counselling. 
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Furthermore, there is a common opinion that people should be given the 
opportunity to make their decision freely and based on adequate information 
about  the  limitations  of  the  test  and  its  physical,  psychology  and  social 
implications, meaning giving informed consent. 
 
The Dutch Act, despite interpretations and enforcement problems, provides 
a basic level of protection against population screening activities that could 
potentially threaten the health of individuals. Yet, we doubt whether the Act 
in its current form can serve as an example for other countries considering 
regulating the use of DTC genetic tests. On the one hand, the Act appears to 
be too liberal compared to the European normative criteria in place.
55 For 
example, the Act does not regulate access to all genetic tests and only 
guarantees the European normative criteria for DTC genetic tests aimed at 
detecting the  (risk indicators of) cancer and (risk indicators of) untreatable 
diseases. On the other hand, the permit system established under the Act 
effectively prevents individuals from getting access to DTC genetic tests in 
the Netherlands if they have questionable validity and utility. However, the 
permit system only applies to the Dutch jurisdiction, see mingly not taking 
into account that its guarantees can easily be by -passed by offering DTC 
genetic tests through the internet and performing the tests outside of the 
Netherlands.  
 
Besides these practical problems and shortcoming it should be noted that 
the  Act  is  not  in  accordance  with  EU  law.  The  definition  of  population 
screening and the licence requirements are ambiguous. The permit system 
of the Act does not meet the rules of the Internal Market because of the 
absence of objective advance announce crit eria. A permit system without 
foreseeable  and  accessible  licence  criteria  could  be  an  invitation  to 
arbitrariness. It could be used to avoid sharp ethical discussions or decisions 
and inhibit scientific knowledge.
56 Furthermore, the Act conflicts with EU law 
because of its enforcement problems. It does not pursue its goal consistently 
and systematically, now that offering and practicing of DTC genetic tests for 
detecting  (risk  indicators  of)  cancer  and  untreatable  diseases  without  a 
licence  is  unlawful
57  and  practicing  without  permission  is  punishable.  In 
addition, the Act conflicts with the Protocol
58  because it seems to be too 
liberal.  Lastly,  it  could  only  be  used  with  necessary  adjustments  as  an 
example for other EU Member States, because it conflicts with the European 
law due to its interpretation and enforcement problems.
59  
Conclusion 
 
Worldwide  there  is  growing  concern  about the  availability  of  DTC  genetic 
tests. Individuals can easily access these tests without adequate information 
and genetic counselling services being provided, let alone safeguards with 
respect to the validity and utility of the tests. This raises the question of 
whether making use of these testing methods to obtain information about 
the presence of genetic risks and hereditary diseases, and thus one‘s future 
health,  truly  reflects  an  expression  of  personal  autonomy.  It  was  argued 
here that there are good public health and human rights reasons to protect 
individuals from subjecting themselves to these tests. 
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The need to regulate the use of DTC genetic tests follows from the standards 
adopted within the context of the Council of Europe and the EU. Despite the 
absence  of  a  comprehensive  European  normative  framework,  important 
principles and norms relevant to the use of DTC genetic tests, and thus its 
supply and access to, have gained recognition on a European level, which 
implies that the validity and utility of DTC genetic tests are crucial factors 
when deciding on allowing the marketing of such a test. Furthermore, DTC 
genetic  tests  with  far  reaching  implications  for  individuals  should  not  be 
allowed without the supervision of a healthcare worker and appropriate non-
directive genetic counselling being offered. Moreover, access to DTC genetic 
tests should be accompanied by rigorous informed consent procedures.  
 
The  Dutch  Act  on  population  screening  is  a  unique  piece  of  legislation 
regulating  the  use  of  screening  programmes  and  also  applying  to  DTC 
genetic tests. Yet in its present form, the Act cannot serve as an example for 
other countries considering the regulation of DTC genetic screening. The Act 
not only suffers from a number of practical problems and shortcomings, but 
is also inconsistent with some EU legal standards. 
 
To conclude, a broad consensus exists among professionals in genetics that 
the implications of DTC genetic tests are far reaching and complex. Such 
testing should not be left to the free forces of the market, but should be 
accompanied  by  adequate  information,  and  informed  consent.  There  is  – 
also in view of these concerns expressed by professionals – not only a need 
to  revise  the  Dutch  Act;  it  is  above  all  important  to  elaborate  on  the 
emerging  body  of  European  legal  standards  applicable  to  DTC  genetic 
screening.  Offering  genetic  tests  directly  to  individuals  via  internet  raises 
complex  legal  questions  that  can  not  merely  be  answered  by  individual 
States. National measures can, moreover, easily be bypassed by making use 
of  cross  border  constructions.  Adequately  protecting  individuals  against 
questionable  testing  kits  therefore  calls  for  international  vigilance  and 
comprehensive measures by the international community, in Europe to start 
with the Council of Europe and the European Union. 
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